[Advances in Leukemia Inhibitors Targeting PI3K/AKT/mTOR Pathway]

Overview

Journal Zhonghua Xue Ye Xue Za Zhi

Specialty Hematology

Date 2015 Oct 20

PMID 26477776

Authors

Le Wang

Yajing Chu

Tao Cheng

Weiping Yuan

Affiliations

Soon will be listed here.

References

Altman J, Sassano A, Kaur S, Glaser H, Kroczynska B, Redig A . Dual mTORC2/mTORC1 targeting results in potent suppressive effects on acute myeloid leukemia (AML) progenitors. Clin Cancer Res. 2011; 17(13):4378-88. PMC: 3131493. DOI: 10.1158/1078-0432.CCR-10-2285. View

Janes M, Limon J, So L, Chen J, Lim R, Chavez M . Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor. Nat Med. 2010; 16(2):205-13. PMC: 4017764. DOI: 10.1038/nm.2091. View

Airiau K, Mahon F, Josselin M, Jeanneteau M, Belloc F . PI3K/mTOR pathway inhibitors sensitize chronic myeloid leukemia stem cells to nilotinib and restore the response of progenitors to nilotinib in the presence of stem cell factor. Cell Death Dis. 2013; 4:e827. PMC: 3824646. DOI: 10.1038/cddis.2013.309. View

Badura S, Tesanovic T, Pfeifer H, Wystub S, Nijmeijer B, Liebermann M . Differential effects of selective inhibitors targeting the PI3K/AKT/mTOR pathway in acute lymphoblastic leukemia. PLoS One. 2013; 8(11):e80070. PMC: 3828226. DOI: 10.1371/journal.pone.0080070. View

Evangelisti C, Ricci F, Tazzari P, Tabellini G, Battistelli M, Falcieri E . Targeted inhibition of mTORC1 and mTORC2 by active-site mTOR inhibitors has cytotoxic effects in T-cell acute lymphoblastic leukemia. Leukemia. 2011; 25(5):781-91. DOI: 10.1038/leu.2011.20. View

Martelli A, Evangelisti C, Chiarini F, McCubrey J . The phosphatidylinositol 3-kinase/Akt/mTOR signaling network as a therapeutic target in acute myelogenous leukemia patients. Oncotarget. 2010; 1(2):89-103. PMC: 2911128. DOI: 10.18632/oncotarget.114. View

Gojo I, Perl A, Luger S, Baer M, Norsworthy K, Bauer K . Phase I study of UCN-01 and perifosine in patients with relapsed and refractory acute leukemias and high-risk myelodysplastic syndrome. Invest New Drugs. 2013; 31(5):1217-27. PMC: 3723766. DOI: 10.1007/s10637-013-9937-8. View

Herman S, Gordon A, Wagner A, Heerema N, Zhao W, Flynn J . Phosphatidylinositol 3-kinase-δ inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals. Blood. 2010; 116(12):2078-88. PMC: 2951855. DOI: 10.1182/blood-2010-02-271171. View

Chiarini F, Grimaldi C, Ricci F, Tazzari P, Evangelisti C, Ognibene A . Activity of the novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 against T-cell acute lymphoblastic leukemia. Cancer Res. 2010; 70(20):8097-107. DOI: 10.1158/0008-5472.CAN-10-1814. View

10.

Amadori S, Stasi R, Martelli A, Venditti A, Meloni G, Pane F . Temsirolimus, an mTOR inhibitor, in combination with lower-dose clofarabine as salvage therapy for older patients with acute myeloid leukaemia: results of a phase II GIMEMA study (AML-1107). Br J Haematol. 2011; 156(2):205-12. DOI: 10.1111/j.1365-2141.2011.08940.x. View

11.

Casanova I, Bosch R, Lasa A, Parreno M, Cespedes M, Brunet S . A celecoxib derivative inhibits focal adhesion signaling and induces caspase-8-dependent apoptosis in human acute myeloid leukemia cells. Int J Cancer. 2008; 123(1):217-26. DOI: 10.1002/ijc.23516. View

12.

Konopleva M, Walter R, Faderl S, Jabbour E, Zeng Z, Borthakur G . Preclinical and early clinical evaluation of the oral AKT inhibitor, MK-2206, for the treatment of acute myelogenous leukemia. Clin Cancer Res. 2014; 20(8):2226-35. PMC: 3989412. DOI: 10.1158/1078-0432.CCR-13-1978. View

13.

Liu P, Cheng H, Roberts T, Zhao J . Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov. 2009; 8(8):627-44. PMC: 3142564. DOI: 10.1038/nrd2926. View

14.

Niemann C, Jones J, Wiestner A . Towards targeted therapy of chronic lymphocytic leukemia. Adv Exp Med Biol. 2013; 792:259-91. DOI: 10.1007/978-1-4614-8051-8_12. View

15.

Mita M, Sankhala K, Abdel-Karim I, Mita A, Giles F . Deforolimus (AP23573) a novel mTOR inhibitor in clinical development. Expert Opin Investig Drugs. 2008; 17(12):1947-54. DOI: 10.1517/13543780802556485. View

16.

Feldman R, Wu J, Polokoff M, Kochanny M, Dinter H, Zhu D . Novel small molecule inhibitors of 3-phosphoinositide-dependent kinase-1. J Biol Chem. 2005; 280(20):19867-74. DOI: 10.1074/jbc.M501367200. View

17.

Buitenhuis M, Coffer P . The role of the PI3K-PKB signaling module in regulation of hematopoiesis. Cell Cycle. 2009; 8(4):560-6. DOI: 10.4161/cc.8.4.7654. View

18.

Sandhofer N, Metzeler K, Rothenberg M, Herold T, Tiedt S, Groiss V . Dual PI3K/mTOR inhibition shows antileukemic activity in MLL-rearranged acute myeloid leukemia. Leukemia. 2014; 29(4):828-38. DOI: 10.1038/leu.2014.305. View

19.

Neri L, Cani A, Martelli A, Simioni C, Junghanss C, Tabellini G . Targeting the PI3K/Akt/mTOR signaling pathway in B-precursor acute lymphoblastic leukemia and its therapeutic potential. Leukemia. 2013; 28(4):739-48. DOI: 10.1038/leu.2013.226. View

20.

Pellicano F, Scott M, Helgason G, Hopcroft L, Allan E, Aspinall-ODea M . The antiproliferative activity of kinase inhibitors in chronic myeloid leukemia cells is mediated by FOXO transcription factors. Stem Cells. 2014; 32(9):2324-37. PMC: 4282530. DOI: 10.1002/stem.1748. View